文献速递临床试验与 GCP流行病学与生物统计

维生素D和钙补充对老年女性癌症发病率的影响:一项随机临床试验

Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2017-01-01

这项为期4年的双盲、安慰剂对照、基于人群的随机临床试验纳入2303名55岁及以上健康绝经后女性,比较维生素D3(2000 IU/d)联合钙(1500 mg/d)与安慰剂对全类型癌症发病率的影响。结果显示,补充组癌症新发诊断45例(3.89%),安慰剂组64例(5.58%),差异未达统计学显著(P=.06)。作者认为在基线血清25-羟基维生素D平均水平为32.8 ng/mL的健康绝经后老年女性中,补充维生素D3和钙与安慰剂相比未显著降低4年全类型癌症风险。

要点

  • 在基线25-羟基维生素D平均32.8 ng/mL的健康绝经后老年女性中,维生素D3联合钙补充未显著降低4年全类型癌症风险(P=.06)。
  • 癌症新发诊断:维生素D3+钙组45例(3.89%)vs 安慰剂组64例(5.58%),差异1.69%(95%CI -0.06%至3.46%)。
  • 不良事件包括肾结石(维生素D3+钙组16例 vs 安慰剂组10例)和血钙升高(6例 vs 2例)。

核心结论

  • 在基线血清25-羟基维生素D平均为32.8 ng/mL的健康绝经后老年女性中,与安慰剂相比,补充维生素D3和钙未显著降低4年全类型癌症风险(P=.06)。
  • 需要进一步研究评估维生素D在癌症预防中的可能作用。

研究设计与样本

  • 为期4年的双盲、安慰剂对照、基于人群的随机临床试验,在31个农村县开展(2009年6月24日至2015年8月26日末次随访)。
  • 共随机分配2303名55岁及以上健康绝经后女性,治疗组1156名,安慰剂组1147名,治疗持续4年。
  • 治疗组接受维生素D3 2000 IU/d和钙1500 mg/d,安慰剂组接受相同安慰剂。
  • 主要结局为全类型癌症(除外非黑色素瘤皮肤癌)的发病率,采用Kaplan-Meier生存分析和比例风险模型评估。

主要发现

  • 2303名随机化女性平均年龄65.2岁(SD 7.0),基线血清25-羟基维生素D平均32.8 ng/mL(SD 10.5),2064名(90%)完成研究。
  • 第1年时,维生素D3+钙组血清25-羟基维生素D为43.9 ng/mL,安慰剂组为31.6 ng/mL。
  • 新发癌症诊断共109例,维生素D3+钙组45例(3.89%),安慰剂组64例(5.58%),差异1.69%(95%CI -0.06%至3.46%;P=.06)。
  • 4年Kaplan-Meier累积发病率:维生素D3+钙组0.042(95%CI 0.032至0.056),安慰剂组0.060(95%CI 0.048至0.076);P=.06。
  • 未校正Cox比例风险回归的风险比为0.70(95%CI 0.47至1.02)。

关键数值与推荐

  • 与安慰剂相比,维生素D3+钙组全类型癌症新发诊断差异为1.69%(95%CI -0.06%至3.46%;P=.06),未达统计学显著。
  • 未校正Cox比例风险回归风险比0.70(95%CI 0.47至1.02)。
  • 可能与研究相关的不良事件:肾结石(维生素D3+钙组16例 vs 安慰剂组10例),血钙升高(维生素D3+钙组6例 vs 安慰剂组2例)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要进一步研究评估维生素D在癌症预防中的可能作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Evidence suggests that low vitamin D status may increase the risk of cancer. OBJECTIVE: To determine if dietary supplementation with vitamin D3 and calcium reduces the risk of cancer among older women. DESIGN, SETTING, AND PARTICIPANTS: A 4-year, double-blind, placebo-controlled, population-based randomized clinical trial in 31 rural counties (June 24, 2009, to August 26, 2015-the final date of follow-up). A total of 2303 healthy postmenopausal women 55 years or older were randomized, 1156 to the treatment group and 1147 to the placebo group. Duration of treatment was 4 years. INTERVENTIONS: The treatment group (vitamin D3 + calcium group) received 2000 IU/d of vitamin D3 and 1500 mg/d of calcium; the placebo group received identical placebos. MAIN OUTCOMES AND MEASURES: The primary outcome was the incidence of all-type cancer (excluding nonmelanoma skin cancers), which was evaluated using Kaplan-Meier survival analysis and proportional hazards modeling. RESULTS: Among 2303 randomized women (mean age, 65.2 years [SD, 7.0]; mean baseline serum 25-hydroxyvitamin D level, 32.8 ng/mL [SD, 10.5]), 2064 (90%) completed the study. At year 1, serum 25-hydroxyvitamin D levels were 43.9 ng/mL in the vitamin D3 + calcium group and 31.6 ng/mL in the placebo group. A new diagnosis of cancer was confirmed in 109 participants, 45 (3.89%) in the vitamin D3 + calcium group and 64 (5.58%) in the placebo group (difference, 1.69% [95% CI, -0.06% to 3.46%]; P = .06). Kaplan-Meier incidence over 4 years was 0.042 (95% CI, 0.032 to 0.056) in the vitamin D3 + calcium group and 0.060 (95% CI, 0.048 to 0.076) in the placebo group; P = .06. In unadjusted Cox proportional hazards regression, the hazard ratio was 0.70 (95% CI, 0.47 to 1.02). Adverse events potentially related to the study included renal calculi (16 participants in the vitamin D3 + calcium group and 10 in the placebo group), and elevated serum calcium levels (6 in the vitamin D3 + calcium group and 2 in the placebo group). CONCLUSIONS AND RELEVANCE: Among healthy postmenopausal older women with a mean baseline serum 25-hydroxyvitamin D level of 32.8 ng/mL, supplementation with vitamin D3 and calcium compared with placebo did not result in a significantly lower risk of all-type cancer at 4 years. Further research is necessary to assess the possible role of vitamin D in cancer prevention. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01052051.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Lappe J, Watson P, Travers-Gustafson D, et al. Effect of Vitamin D and Calcium Supplementation on Cancer Incidence in Older Women: A Randomized Clinical Trial. JAMA. 2017. PMID: 28350929. doi:10.1001/jama.2017.2115

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。